- Home
- RPRX vs RVTY Comparison
RPRX vs RVTY Comparison
Compare RPRX & RVTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- RVTY
- Stock Information
- Founded
- RPRX 1996
- RVTY 1937
- Country
- RPRX United States
- RVTY United States
- Employees
- RPRX N/A
- RVTY N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- RVTY Biotechnology: Laboratory Analytical Instruments
- Sector
- RPRX Health Care
- RVTY Industrials
- Exchange
- RPRX Nasdaq
- RVTY Nasdaq
- Market Cap
- RPRX 14.0B
- RVTY 13.9B
- IPO Year
- RPRX 2020
- RVTY N/A
- Fundamental
- Price
- RPRX $33.88
- RVTY $115.55
- Analyst Decision
- RPRX Strong Buy
- RVTY Buy
- Analyst Count
- RPRX 5
- RVTY 11
- Target Price
- RPRX $41.60
- RVTY $137.73
- AVG Volume (30 Days)
- RPRX 4.6M
- RVTY 967.8K
- Earning Date
- RPRX 02-11-2025
- RVTY 01-31-2025
- Dividend Yield
- RPRX 2.60%
- RVTY 0.24%
- EPS Growth
- RPRX N/A
- RVTY N/A
- EPS
- RPRX 1.91
- RVTY 2.20
- Revenue
- RPRX $2,263,576,000.00
- RVTY $2,755,026,000.00
- Revenue This Year
- RPRX $29.18
- RVTY $4.83
- Revenue Next Year
- RPRX $9.99
- RVTY $6.20
- P/E Ratio
- RPRX $17.69
- RVTY $52.45
- Revenue Growth
- RPRX N/A
- RVTY 0.16
- 52 Week Low
- RPRX $24.05
- RVTY $97.32
- 52 Week High
- RPRX $34.16
- RVTY $129.50
- Technical
- Relative Strength Index (RSI)
- RPRX 80.55
- RVTY 46.77
- Support Level
- RPRX $32.28
- RVTY $113.07
- Resistance Level
- RPRX $34.20
- RVTY $116.79
- Average True Range (ATR)
- RPRX 0.71
- RVTY 2.96
- MACD
- RPRX 0.02
- RVTY -0.30
- Stochastic Oscillator
- RPRX 89.40
- RVTY 40.38
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About RVTY Revvity Inc.
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.